- ADVERTISEMENT
-
Most Popular
- ADVERTISEMENT
Search Results
240 results for MJN
Is the Baby Bust Finished?
America’s decline in fertility appears to be leveling off, and a new boom could be just a couple years away. If so, what should investors…
Sears Slammed After Store Closings — Tuesday’s IP Market Recap
Sears shares plummet 27% after announcing the company would close 100 to 120 Sears and Kmart locations.
21 Upgraded Blue-Chip Stocks to Buy
After taking a close look at the latest data on institutional buying pressure and each company’s fundamental health, I decided to revise rankings for many…
Mead Johnson’s Margins Are Making Abbott Jealous
The profit war is on between the top baby forumula makers.
Abbott Milking More Profits By Imitating Baby Formula Business
Baby formula maker Mead’s rising success has competitor Abbott Laboratories trying desperately to catch some of the momentum, which is showing no signs of slowing…
A Look at the Week Ahead – (BMY, JBL, OSIP, RHT, SQNM, V)
Trading ideas for the week include BMY, JBL, OSIP, RHT, SQNM, and V.
Is Abbott’s Spinoff the Beginning of a Trend?
A look at Abbott Labs’ (ABT) breakup indicates splitting up may be good medicine for other diversified health care companies.
Abbott Labs Spinoff Looks Like the Right Move
Shareholders would likely be better served by the company’s prescription drug business standing alone. Here’s why.
55 Trades to Make Before Earnings Season Ends
Earnings season continues, and I’ve provided you with my most recent grades on 55 stocks; take a look and trade accordingly
Will Less Be More for Big Pharma?
Companies seem split on the asset selloff strategy.
Pfizer Shares – 3 Pros, 3 Cons
Will a robust pipeline offset the loss of patent protection on key drugs?
Is Pfizer Move to Sell Non-Pharma Divisions Bad Medicine?
Pfizer has said it will shed its nutritional and animal health businesses to pump more money into its drug pipeline. But is the move risky?
Should I Buy Bristol-Myers Squibb? 3 Pros, 3 Cons
Its deal to buy diabetes-drug maker Amylin will help, given that market’s potential. Still, patent expirations loom large and won’t be easily overcome.
Mead Johnson Bounce Followed J&J Script
Mead Johnson’s recent Enfamil scare sent many investors packing — but those who stuck with the stock could soon be rewarded.
The Dow Jones Transportation Average Is Showing Cracks
A breakdown isn’t imminent in the Dow Jones Transportation Average, but traders should keep a close eye on it.
Investing in Generation Y and the Next Great Baby Boom
Much like the Baby Boomers did more to shape the U.S. over the past 50 years, their children — Generation Y — will shape the…
52 Trades to Beat the Mutual Fund Slump
I’ve taken some of the guesswork out of stock picking for you by updating my ratings for these 52 stocks.
Mead Johnson Might Be One to Shed
Sales for Mead Johnson Nutrition’s baby food have been robust, but dividends and earnings growth have been mediocre.
IPOs Investing – Why You Want to Invest in IPOs NOW!
We are looking at the hottest IPO market we have seen in years, and you’ll be kicking yourself if you miss out.
50 Ways to Make Market Swings Work For You
With the stock market moving around in earnings season, now is the time to look through our buy and sell chart looking for ways to…
What To Make Of Tuesday’s Surprising Market Move
Wall Street clearly made up for the shortened trading week with a broad rally on Tuesday. Here’s our new research on 50 stocks in Portfolio…
4 Blue Chips Ripe for Spin-Offs
Spin offs from Motorola and Marathon hint at four other companies that may have spinoffs soon – Pfizer, Yahoo, Symantec and GE.
10 – 10 of 240 results
